Lura

Take Lurasidone orally once daily with food (at least 350 calories). Taking it without food significantly decreases its absorption.

Lurasidone primarily acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, and as a partial agonist at serotonin 5-HT1A receptors. It also has antagonistic activity at adrenergic alpha2C receptors and serotonin 5-HT7 receptors. This combined receptor activity is believed to contribute to its therapeutic effects on mood, thought, and behavior.

• Known hypersensitivity to Lurasidone or any component of the formulation.
• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole).
• Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort, phenytoin).

Store at room temperature (20°C to 25°C), protected from light and moisture. Keep out of reach of children.

Symptoms of overdose may include drowsiness, sedation, tachycardia, and hypotension. There is no specific antidote for Lurasidone overdose. Management should involve supportive care, maintaining an adequate airway, oxygenation, and ventilation, and monitoring cardiac function and vital signs. Gastric lavage and activated charcoal may be considered.

Pregnancy: Category C. Lurasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Lactation: It is not known whether Lurasidone is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

• Known hypersensitivity to Lurasidone or any component of the formulation.
• Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole).
• Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort, phenytoin).

Store at room temperature (20°C to 25°C), protected from light and moisture. Keep out of reach of children.

Symptoms of overdose may include drowsiness, sedation, tachycardia, and hypotension. There is no specific antidote for Lurasidone overdose. Management should involve supportive care, maintaining an adequate airway, oxygenation, and ventilation, and monitoring cardiac function and vital signs. Gastric lavage and activated charcoal may be considered.

Pregnancy: Category C. Lurasidone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms. Lactation: It is not known whether Lurasidone is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.